Steroid-toxicity Insights Roundup
Insights
Promising Monoclonal Antibody Offers New Steroid-Sparing Hope for IgG4-RD
Results from the Phase 3 MITIGATE trial of inebilizumab have raised hopes of a steroid-sparing treatment for IgG4-RD.
The Digital Tool Helping Neurologists Be Patient-Loving Physicians
Neelam Goyal, MD, has been leading a pioneering, retrospective, real-world study exploring the use of the Steritas GTI-MD in myasthenia gravis.
"A patient who already has PTSD is going to have a more sensitive nervous system that will be more reactive to the addition of an exogenous stressor such as steroids, creating a medication-based trigger.”
In the News
An Interview with Dr John Stone, Steritas
The Journal for Clinical Studies recently sat down with the Chair of our Scientific Advisory Board, John Stone MD, MPH, to discuss the growing "open secret": the epidemic of steroid-toxicity.
Experience the STOX? Digital Platform
Your free trial of the GTI-MD is waiting for you. Experience it now >
Steritas is working toward a world free of steroid dependency, enabling the measurement and monitoring of steroid-toxicity to optimize the treatment of inflammatory diseases and improve the quality of patient care around the world.
Learn more at steritas.com.
Sincerely,
CEO, Steritas